The Manila Times51m
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi”) to ...
SWI swissinfo.ch1h
Stock Meltdown Fuels Worst S&P 500 Day Since 2020: Markets Wrap
The “America First” trade is unraveling in the sweeping turmoil in global markets, with stocks acutely exposed to the US ...